NRAS and melanoma: Notably, BRAF, a downstream activator in the RAS pathway is mutated in nearly 70% of human melanoma (BRAFV600E activating mutation) while NRAS activating mutations occurs in 30% of melanomas (NRASQ61L activating mutation) [3].